Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarat Chandarlapaty

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
Cancer Discovery|May 12, 2012
Negative feedback and adaptive resistance to the targeted therapy of cancerSarat Chandarlapaty
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2019
Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 InhibitorsSarat Chandarlapaty, Pedram Razavi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Molecular pathways: HER3 targeted therapyKinisha Gala, Sarat Chandarlapaty
Expert Review of Anticancer Therapy|February 24, 2011
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesDevika Gajria, Sarat Chandarlapaty
Cold Spring Harbor Perspectives in Medicine|January 8, 2023
Emerging Therapies for Breast CancerShom Goel, Sarat Chandarlapaty
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?Sarat Chandarlapaty, Shanu Modi
Nature Reviews. Clinical Oncology|January 9, 2024
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Nature Reviews. Clinical Oncology|August 2, 2024
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Cancer Discovery|March 3, 2019
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast CancerJoshua Z Drago, Sarat Chandarlapaty, Komal Jhaveri
Cancer Discovery|April 3, 2023
ADCs or: How I Learned to Stop Worrying and Love ChemotherapyAvantika Gupta, Joshua Z Drago, Sarat Chandarlapaty
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
Cancer Discovery|May 12, 2012
Negative feedback and adaptive resistance to the targeted therapy of cancerSarat Chandarlapaty
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2019
Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 InhibitorsSarat Chandarlapaty, Pedram Razavi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2014
Molecular pathways: HER3 targeted therapyKinisha Gala, Sarat Chandarlapaty
Expert Review of Anticancer Therapy|February 24, 2011
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapiesDevika Gajria, Sarat Chandarlapaty
Cold Spring Harbor Perspectives in Medicine|January 8, 2023
Emerging Therapies for Breast CancerShom Goel, Sarat Chandarlapaty
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2011
Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs?Sarat Chandarlapaty, Shanu Modi
Nature Reviews. Clinical Oncology|January 9, 2024
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Nature Reviews. Clinical Oncology|August 2, 2024
Author Correction: Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectivesAntonio Marra, Sarat Chandarlapaty, Shanu Modi
Cancer Discovery|March 3, 2019
Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast CancerJoshua Z Drago, Sarat Chandarlapaty, Komal Jhaveri
Cancer Discovery|April 3, 2023
ADCs or: How I Learned to Stop Worrying and Love ChemotherapyAvantika Gupta, Joshua Z Drago, Sarat Chandarlapaty
Pageof 16